



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Sunday, November 22, 2009

R-Biopharm Inc.

[View the current R-Biopharm Inc. Page on BioPortfolio.com](http://www.bioportfolio.com/bioporcorporate/28978-R-Biopharm+Inc..html)

(<http://www.bioportfolio.com/bioporcorporate/28978-R-Biopharm+Inc..html>)

Contact Details:

7950 Old US 27 South

Marshall

Michigan

49068

United States of America

Tel: 1 269 7 89 30 33

Fax: 1 269 7 89 30 70

Email: webmaster@r-biopharm.com

R-Biopharm AG was founded in 1988 as a subsidiary of the company Röhm AG in Darmstadt. In 1991 R-Biopharm was acquired by Dr. Ralf Dreher through a management buy out. The main activity is the development, production and marketing of two different product lines. 1) Enzyme immunoassays for the detection of residues in food and feed

This product line contains test systems for the rapid screening for mycotoxins, hormones and anabolics, antibiotics, vitamins, food allergens and some other parameters

2) Enzyme immunoassays for the detection of human infectious diseases

The product line contains test systems in the field of stool diagnostics, infectious disease, serology and allergy testing

All products, agri/food diagnostics as well as the clinical diagnostics, are distributed world-wide under the trademarks RIDASCREEN and RIDA via an international distributor network or through own daughter companies like in the US (R-Biopharm Inc.), in the UK (R-Biopharm Rhône Ltd), in France (R-Biopharm France) and in Italy (R-Biopharm Italia).

Since November 1996 the quality management of R-Biopharm is certified according to DIN EN ISO 9001 and DIN EN 46001 (medical products). Certification according to the Quality Management Standard ISO 13485 (Medical product) took place in 2003.

Since January 1st 2000 R-Biopharm is the world-wide exclusive distributor for the Boehringer Mannheim Roche enzymatic tests.

Press Releases on R-Biopharm Inc.:

[REGURIN\(R\) XL \(trospium chloride\) Once Daily Tablets Now Available in the UK for the Treatment of Overactive Bladder](#)

7th September,
2009

LONDON, September 7 /PRNewswire/ -- Regurin(R) XL (trospium chloride), a once-daily, prolonged-release capsule to treat patients with overactive bladder (OAB) has been launched in the UK. Regurin(R)

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus	20th July, 2009		ROCKVILLE, Maryland and LONDON, July 20 /PRNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R))
PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June	10th June, 2009	PharmaNet Development Group, Inc.	PRINCETON, N.J., June 10 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical
Discoverers of Small Regulatory RNAs and Cholesterol-Lowering Drugs to Receive Lasker Awards for Medical Research	11th September, 2008	The Albert and Mary Lasker Foundation	/ADVANCE/ NEW YORK, Sept. 11 /PRNewswire/ -- The 2008 Albert Lasker Medical Research Awards (http://www.laskerfoundation.org) were announced today. First presented in 1946, the Lasker Awards are
BIOPHEX2004 promotes value innovation in the biopharmaceutical industry	1st December, 2003	Reedexpo	BIOPHEX2004 promotes value innovation in the biopharmaceutical industry By Kevin Richards Industry Vice President, Reed Exhibitions In its brief

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

